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Abstract  
AIM: The study analyzed the level of cytokines playing the significant role in the diagnosis of 
circulatory system diseases and total cardiovascular risk. 
 
MATERIAL AND METHODS: The study involved 1,244 residents of Karaganda region. We had 
studied baseline participant characteristics, in addition to calculating the total cardiovascular risk 
and assessment of Fatty Acid Binding Proteins 3 (FABP3), Fatty Acid Binding Proteins 4 (FABP4) 
and N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) level. 
 
RESULTS: The results showed the combination of high cardiovascular risk (CVR) with increased 
titers of cardiac markers, reflecting common pathogenic mechanisms in its development, among 
residents of Karaganda region.
 
CONCLUSION: The combination of high CVR with the increased titers of cardiac markers showed 
common pathogenic mechanisms in its development, and support the diagnostic and prognostic 
value of these parameters among residents of Karaganda region, and also reflects the possibility to 
include these cardiac markers in the program of screening survey of population for early prevention 
of cardiovascular disease and its complications.
 
 
 
 
 
Introduction 
 
 Currently, according to the data of many 
epidemiological studies cardiovascular disease 
remains the leading cause of death in our country and 
abroad [1-7]. Scientists interested the problem of 
predicting of complications of cardiovascular disease 
(CVD) for a long time. One of its decisions was the 
conducting of the large study by the experts of the 
European Society of Cardiology. Prospective studies 
with the participation of more than 205 thousand 
patients were conducted in 12 European countries, 
including Russia (State Research Center for 
Preventive Medicine) [8].  
The result of this 27-years study was the 
formation of the European model SCORE (Systemic 
Coronary Risk Evaluation). Blood cardiac markers 
found the wide use, reflecting the most of section of 
pathophysiological process and playing the definite 
prognostic role, in addition to determining of total 
cardiovascular risk for early diagnosis of CVD [9-15]. 
The value of each of the selected cardiac markers 
studied in detail in the pathogenesis and diagnostics 
of arterial hypertension, congestive heart failure, 
atherosclerosis, myocardial infarction and stroke. 
However, there is insufficient data on the combination 
of the levels of FABP3, FABP4 and NT-proBNP with a 
total risk of cardiovascular disease. 
The aim of our work was to analyse the role of 
FABP3, FABP4 and NT-proBNP in the diagnosis of 
total cardiovascular risk (CVR). 
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Material and Methods 
 
In addition to determining the levels of 
FABP3, FABP4 and NT-proBNP, the following work 
with the population was conducted: survey, 
anthropometry, blood pressure measurement, 
determination of blood glucose and total cholesterol. It 
was conducted the immunological multiplex study of 
the blood of 1,244 people aged 18-65, including 872 
women and 372 men. Pregnant women, people with 
decompensated cardiac, endocrinology, nephrology 
pathologies, as well as persons with severe mental 
illness and oncological diseases were excluded from 
the study. The index of total cardiovascular risk 
SCORE was calculated for all examined people [8].  
Determination of cardiac markers was carried 
out by immunofluorescence method using XMap 
technology on the Bioplex 3D with Human CVD 
Magnetic Bead Panel 1. We determined the levels of 
FABP3, NT-proBNP, FABP-4. FABP3 is heart form of 
protein, binding the fatty acid, and it is detected in 
patients with acute myocardial infarction, heart failure. 
It evidences of permanent myocardium damage and is 
associated with worsening prognosis and high 
mortality [16, 17]. N-terminal fragment of brain 
natriuretic peptide (NT-proBNP) is evaluated as a 
predictor of cardiac events and lethal outcomes in 
acute and chronic heart failure [18], and also plays a 
significant role in the formation of atherosclerosis [9, 
19]. Increased level of FABP-4, is associated with 
obesity, insulin resistance, hypertension, 
atherosclerosis [12, 20-21]. 
 
Statistical analysis 
For statistical analysis, we used IBM SPSS 
Statistics, Version 24. Data analysis was performed 
with the significance level α = 0.05. Check on the 
normal distribution of quantitative data was performed 
using the Kolmogorov-Smirnov test. Description of the 
quantitative data was carried out  bofy median and 
quartiles. For qualitative data, it was calculated the 
proportion of individuals with traits of interest and 95% 
confidence interval of the proportion calculated by 
Klopper-Pearson method. We used U criterion of 
Mann-Whitney to compare the independent samples. 
 
 
Results 
 
Table 1 and 2 show the baseline 
characteristics of the examined people depending on 
gender. The median of age women included in the 
study was more than median of male (56.00, Q25 – 
51.00; Q75 – 61.00 and 52.00, Q25 – 45.00; Q75 – 
59.00, p < 0.001). Assessing the BMI noted that both 
populations are overweight, and women BMI was 
significantly greater (29.38, Q25 – 25.96; Q75 – 33.67 
and 27.22, Q25 – 24.00; Q75 – 30.49, p < 0.001).  
Table 1: Qualitative baseline participant characteristics 
 Men Women p-value 
N Median Q25 Q75 N Median Q25 Q75 
Age, years 372 52.00 45.00 59.00 872 56.00 51.00 61.00 0.000 
BMI, kg/m^2 370 27.22 24.00 30.49 867 29.38 25.96 33.67 0.000 
Systolic BP, BP, 
mm Hg 
369 130.0 120.0 140.0 869 130.0 120.0 145.0 0.072 
Cholesterol, 
mmol/L 
366 4.975 3.870 5.900 866 5.140 3.870 6.120 0.056 
 
The proportion of women with hypertension 
was much higher than men – 59.08% and 37.20%, 
respectively (p < 0.001), though the median of systolic 
arterial pressure had no differences. Total cholesterol 
levels were increased in both groups, but higher rates 
were observed in women (5.140, Q25 – 3.87; Q75 – 
6.12 and 4.97, Q25 – 3.87; Q75 – 5.90, p = 0.005). 
Also, the higher percentage of smokers was observed 
in male population (45.78% and 10.76% respectively, 
p < 0.001). 
Table 2: Quantitative baseline participant characteristics 
 Men Women  
p-value N % 95% СI N % 95% СI 
Arterial 
hypertension 
138 37.20 32.26;42.34 514 59.08 55.73;62.37 0.000 
Smoking 168 45.78 40.60;51.03 93 10.76 8.78;13.02 0.000 
 
The results of immunological studies of blood 
for cardiac markers are described in tables 3-5. The 
results of the general population (Table 3) show that 
the median of values of all three cardiac markers was 
significantly higher in the group of high CVR (p < 
0.05). 
Table 3: Comparison of cardiac markers indicators (pg/ml) in 
the groups with high and low total cardiovascular risk in the 
general population 
 SCORE, high risk SCORE, low risk p-value 
N Median Q25 Q75 N Median Q25 Q75 
FABP 3 942 2099.06 1449.08 3088.71 302 1686.71 1153.73 2432.48 0.000 
NT- 
proBNP 
942 78.63 49.29 109.25 302 67.91 44.25 94.05 0.002 
FABP 4 942 15417.30 9148.77 24441.47 302 14587.26 8855.39 20493.94 0.019 
 
Table 4 shows the results of comparing of 
cardiac markers level in men – only the NT-proBNP 
level was significantly higher in the group of high CVR 
(78.49, Q25 – 50.58; Q75 – 110.28 and 65.91, Q25 – 
43.99; Q75 – 90.10, p < 0.05). The differences were 
not observed in FABP 3 and FABP 4. 
Table 4: Comparison of cardiac markers indicators (pg/ml) in 
the groups with high and low total cardiovascular risk in men 
 SCORE, high risk SCORE, low risk p-value 
N Median Q25 Q75 N Median Q25 Q75 
FABP 3 304 1952.23 1396.90 2936.02 68 1676.68 1336.16 2290.45 0.065 
NT- 
proBNP 
 
304 
 
78.49 
 
50.58 
 
110.28 
 
68 
 
65.91 
 
43.99 
 
90.10 
 
0.039 
FABP 4 304 14085.63 7711.29 19704.68 68 14685.49 9903.65 21687.69 0.552 
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In the female population (Table 5), with high 
probability, the median of titers FABP 3 (2204.09, Q25 
– 1492.74; Q75 – 3277.31 and 1693.39, Q25 – 
1101.83; Q75 – 2442.27, p < 0.001), NT-proBNP 
(78.66, Q25 – 49.00; Q75 – 108.39 and 68.25, Q25 – 
44.25; Q75 – 98.13, p < 0.05) and FABP 4 (16791.89, 
Q25 – 9961.06; Q75 – 26256.08 and 14544.90, Q25 
– 8823.34; Q75 – 20112.41, p < 0.001) was higher in 
the group with high total cardiovascular risk. 
Table 5: Comparison of cardiac markers (pg/ml) in the groups 
with high and low total cardiovascular risk in women 
 SCORE, high risk SCORE, low risk p-value 
N Median Q25 Q75 N Median Q25 Q75 
FABP 3 638 2204.09 1492.74 3277.31 234 1693.39 1101.83 2442.27 0.000 
NT- 
 
proBNP 
 
638 
 
78.66 
 
49.00 
 
108.39 
 
234 
 
68.25 
 
44.25 
 
98.13 
 
0.021 
FABP 4 638 16791.89 9961.06 26265.08 234 14544.90 8823.34 20112.41 0.000 
 
 
 
Discussion 
 
We investigated the level of cardiac form of 
protein, binding the fatty acids 3 (FABP3), N-terminal 
prohormone of natriuretic peptide (NT-pro-BNP) and 
protein, binding fatty acids 4 (FABP 4) in people with 
low and high total cardiovascular risk. The main 
results of this study showed that the median of all 
three cardiac markers was higher in the group with 
high CVR. Differences were observed only in the male 
population, where the rate of only one substance (NT-
proBNP) had the significantly greater median in the 
group of persons with high CVR. 
We chose FABP3 as one of the cardiac 
markers localised in cardiac myocytes. It provides the 
transport of fatty acids, as one of the most important 
energy resources of heart, to mitochondria. Also, it 
protects against free radicals accumulated as a result 
of myocardial ischemia [13, 22-24]. Thus, the higher 
titers of this protein in the peripheral blood are one of 
the earliest and specific indicators of myocardial 
damage of various origins, whether ischemia, 
cardiomyopathy, heart failure [17, 20, 25-26]. 
The results of our study showed that in the 
group women with high total CVR the median of titers 
of FABP3 significantly higher than in the low-risk 
group, in a case of the male population it was no 
differences. This indicates about damaged 
myocardium in the group with high CVR and reflects 
the diagnostic and prognostic value of this indicator in 
patients with cardiovascular disease. This can also be 
explained by the high number of women in the study 
and by the results of the comparison of general 
characteristics, in which more percentage of persons 
were women with hypertension and the highest 
median of total cholesterol. 
The second cardiac marker, used in this 
study, was NT-pro-BNP. The peptide is released in 
response to tension and hypoxia of cardiomyocytes 
and is used as a diagnostic and prognostic indicator of 
chronic heart failure, the risk of fatal complications 
(myocardial infarction, stroke) [18], and also has an 
effect on the vascular wall, which allows us to 
estimate the risk of development of atherosclerosis 
and hypertension [9, 11, 19, 27]. The analysis of the 
level of titles of NT-pro-BNP shows that the median 
value in the male and female populations has 
differences. This may indicate damaged myocardium 
in the studied group with high CVR and reflects the 
diagnostic and prognostic value of this indicator in 
patients with cardiovascular disease. 
The last cardiac marker, which was used in 
the study, was FABP 4. This substance is adipokine, 
secreted by adipose tissue (adipocytes), and is 
involved in the regulation of energy metabolism and 
inflammation process [12]. According to the results of 
several large studies, the increased titers of this 
marker associated with obesity, metabolic syndrome, 
and the risk of developing of the resistance to insulin, 
diabetes mellitus of type 2 and as a consequence 
increasing cardiovascular risk [12-14, 22]. In our 
study, the median titers of the protein are higher in 
women with high CVR. In the male population, the 
differences between these values and the level of 
CVR are not revealed. These results correlate with the 
presence of large BMI values in the female population. 
As a result, the combination of high CVR with 
the increased titers of cardiac markers showed 
common pathogenic mechanisms in its development, 
and support the diagnostic and prognostic value of 
these parameters among residents of Karaganda 
region, and also reflects the possibility to include 
these cardiac markers in the program of screening 
survey of population for early prevention of 
cardiovascular disease and its complications. 
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